Facebook
X
LinkedIn
ForwardSUD - Consequences of Substance Use During Pregnancy and Treatment Options
This activity examines opioid use disorder (OUD) during pregnancy, including its causes, prevalence, comorbidities, and medical complications affecting both mother and infant. Participants will review evidence-based treatment approaches—comparing methadone and buprenorphine (mono and combination formulations)—and explore best practices for managing neonatal opioid withdrawal syndrome (NOWS/NAS). The session also highlights the importance of comprehensive psychosocial and behavioral support within perinatal care. Attention will be given to recognizing and addressing co-occurring substance use and mental health conditions to develop a patient-centered, whole-person care plan that optimizes outcomes for pregnant individuals and their newborns.
Target Audience: Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers
Learning Objectives:
- Describe the impact of opioid use disorder (OUD) during pregnancy on maternal and neonatal outcomes, including the presentation and management of neonatal opioid withdrawal syndrome (NOWS/NAS).
- Compare evidence-based pharmacologic treatments for OUD in pregnancy—specifically methadone and buprenorphine (mono and combination formulations)—and identify components of comprehensive psychosocial support services recommended in perinatal care.
- Recognize common co-occurring substance use (e.g., alcohol, stimulants, cannabis, nicotine) and psychiatric or psychosocial conditions in pregnant individuals with OUD, and incorporate these into a patient-centered, whole-person care plan.
Target Audience
Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers
Learning Objectives
Upon completion of this activity, participants will be able to:
1. Describe the impact of opioid use disorder (OUD) during pregnancy on maternal and neonatal outcomes, including the presentation and management of neonatal opioid withdrawal syndrome (NOWS/NAS).
2. Compare evidence-based pharmacologic treatments for OUD in pregnancy—specifically methadone and buprenorphine (mono and combination formulations)—and identify components of comprehensive psychosocial support services recommended in perinatal care.
3. Recognize common co-occurring substance use (e.g., alcohol, stimulants, cannabis, nicotine) and psychiatric or psychosocial conditions in pregnant individuals with OUD, and incorporate these into a patient-centered, whole-person care plan
Faculty & Credentials
Michelle Lofwall, MD, DFAPA, DFASAM
University of Kentucky College of Medicine
Disclosure Information
All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.
None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.
Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation
Available Credit
- 1.00 ACPE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.
- 1.00 AMA PRA Category 1 Credit™
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Enduring activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC (UK Healthcare CECentral)
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).
- 1.00 ASWB
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course.
Social workers completing this course receive 1.00 clinical continuing education credit(s).